|0.58|| +0.04 / +7.41%|
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. The companies business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.
|David J. Mazzo||Chief Executive Officer & Director|
|Joseph Talamo||Chief Financial Officer & Senior Vice President|
|Douglas W. Losordo||Chief Medical Officer & SVP-Regulatory Affairs|
|Greg Berkin||Vice President-Information Technology|
|Robert A. Preti||Director, Chief Technical Officer & Senior VP|